Vivos Therapeutics (VVOS) Cash from Financing Activities (2020 - 2026)

Vivos Therapeutics (VVOS) has 6 years of Cash from Financing Activities data on file, last reported at $6.1 million in Q1 2026.

• Quarterly Cash from Financing Activities changed N/A year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.3 million (changed N/A YoY) and the FY2025 annual result came in at $18.6 million, up 3.82% from the prior year.
• Cash from Financing Activities rose to $6.1 million in Q1 2026 per VVOS's latest filing, from $4.3 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $7.4 million in Q2 2024 and bottomed at $2.8 million in Q3 2025.
• The 4-year median for Cash from Financing Activities is $3.8 million (2024), against an average of $4.7 million.
• The widest annual swing landed in 2024, when Cash from Financing Activities plunged 50.58%; it then surged 41.94% in 2025.
• Tracing VVOS's Cash from Financing Activities over 4 years: stood at $3.6 million in 2023, then fell by 14.41% to $3.1 million in 2024, then jumped by 41.94% to $4.3 million in 2025, then soared by 40.92% to $6.1 million in 2026.
• Per Business Quant, the three latest VVOS Cash from Financing Activities figures stand at $6.1 million (Q1 2026), $4.3 million (Q4 2025), and $2.8 million (Q3 2025).

Peer Comparison